about
Clinical implementation of pharmacogeneticsVariants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancerSystematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].Identification of new SNPs associated with severe toxicity to capecitabine.Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase geneEfficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocolUse of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicityUsing pharmacogenetics to prevent severe adverse reactions to capecitabineDrug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecanCurrent use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution
P50
Q28072159-506FA686-2D95-4E86-810D-E5C69A07DCD1Q35742555-146DD35A-8C7C-48A7-B4EA-74921E3A5D95Q40121784-34AE4486-2F5B-494F-9AD9-B0DD68950FE8Q41438607-D2277C16-F33B-4392-BF1A-141BB277505DQ47835547-3005C92A-F162-42B8-A8C6-3C57F50587E1Q47912298-AEA0DA44-3E61-49FF-8C29-B3B1BE83A557Q48189225-3067F7AC-C601-464E-BE1B-5B8F67C0E919Q53088528-069AD200-D6CC-4308-8925-F2A9DB73B28BQ57815793-FA180D29-382E-41B4-97CF-921899893007Q86127937-6DFC654D-E1E6-406D-AB01-B76DFFB7C89EQ88608742-896D7B30-8BBD-46BA-9B72-5B4A7902F178Q88609467-2FE5090D-8607-4139-B176-2AD9EF616268Q89338346-CFF44A27-D63E-48ED-A3CE-22DAAA6C9A41Q91433812-E6700266-0670-43BA-B3DF-FC8F0744E13FQ91651252-5EB1159C-5330-453B-A3B6-4AB51F3DD872
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xandra García-González
@ast
Xandra García-González
@en
Xandra García-González
@es
Xandra García-González
@nl
type
label
Xandra García-González
@ast
Xandra García-González
@en
Xandra García-González
@es
Xandra García-González
@nl
prefLabel
Xandra García-González
@ast
Xandra García-González
@en
Xandra García-González
@es
Xandra García-González
@nl
P106
P21
P31
P496
0000-0002-6269-7953